Physician profile
James Reilly
NPI 1558466615
$1,528.78
in general payments reported to CMS, 2019-2025
23 companies · $242 in 2025
The $242 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $24.47 · 2021: $181 · 2022: $165 · 2023: $216 · 2024: $293 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $300.16 | 2019-2025 | Bexsero |
| Sanofi-Aventis U.S. LLC | $237.86 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $209.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Cranial Technologies, INC | $188.58 | 2020-2025 | Doc Band |
| Pfizer INC. | $81.66 | 2019-2025 | |
| Seqirus USA INC | $67.04 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Supernus Pharmaceuticals, INC. | $64.52 | 2021 | |
| Aytu Biopharma, INC. | $56.75 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.64 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $39.32 | 2023 | Jornay Pm |
| Cumberland Pharmaceuticals, INC. | $23.81 | 2024 | Kristalose |
| Ars Pharmaceuticals Operations, INC. | $20.36 | 2025 | Neffy |
| Alk-Abello, INC | $19.98 | 2025 | Neffy |
| Alexion Pharmaceuticals, INC. | $19.17 | 2022 | |
| Novo Nordisk INC | $19.17 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meridian Bioscience INC. | $18.98 | 2019 | |
| Sanofi Pasteur INC. | $18.77 | 2023 | |
| Neos Therapeutics, LP | $18.12 | 2022 | |
| Phadia US INC. | $17.03 | 2023 | Immunocap |
| Corium, LLC | $14.72 | 2022 | |
| Kaleo, INC. | $14.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.14 | 2024 | Flumist Quadrivalent |
| Becton, Dickinson and Company | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.